# An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma

> **NCT00563056** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 227 (actual)

## Conditions studied

- Asthma Bronchiale

## Interventions

- **DRUG:** Flutiform
- **DRUG:** Flixotide plus Foradil

## Key facts

- **NCT ID:** NCT00563056
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563056, "An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00563056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*